Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin A M Gale

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Diabetes Care|January 24, 2012
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survivalCraig J Currie, Chris D Poole, Sara Jenkins-Jones, et al.
Diabetes|March 29, 2005
Is puberty an accelerator of type 1 diabetes in IL6-174CC females?Kathleen M Gillespie, Runa Nolsøe, Virginie M Betin, et al.
The Journal of Clinical Endocrinology and Metabolism|August 5, 2004
Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United KingdomA Paul Lambert, Kathleen M Gillespie, Glenys Thomson, et al.
Lancet (London, England)|November 9, 2004
The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypesKathleen M Gillespie, Steven C Bain, Anthony H Barnett, et al.
The Lancet. Diabetes & Endocrinology|December 17, 2021
Diabetes and the WHO Model List of Essential MedicinesDavid Beran, Stéphane Besançon, Margaret Ewen, et al.
Diabetes|October 27, 2006
Islet autoimmunity in children with Down's syndromeKathleen M Gillespie, Rachel J Dix, Alistair J K Williams, et al.
Diabetes|October 27, 2004
Activating mutations in the KCNJ11 gene encoding the ATP-sensitive K+ channel subunit Kir6.2 are rare in clinically defined type 1 diabetes diagnosed before 2 yearsEmma L Edghill, Anna L Gloyn, Kathleen M Gillespie, et al.
Diabetes Care|December 19, 2008
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart AssociationJay S Skyler, Richard Bergenstal, Robert O Bonow, et al.
Circulation|December 20, 2008
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart AssociationJay S Skyler, Richard Bergenstal, Robert O Bonow, et al.
Journal of the American College of Cardiology|January 17, 2009
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart AssociationJay S Skyler, Richard Bergenstal, Robert O Bonow, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Diabetes Care|January 24, 2012
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survivalCraig J Currie, Chris D Poole, Sara Jenkins-Jones, et al.
Diabetes|March 29, 2005
Is puberty an accelerator of type 1 diabetes in IL6-174CC females?Kathleen M Gillespie, Runa Nolsøe, Virginie M Betin, et al.
The Journal of Clinical Endocrinology and Metabolism|August 5, 2004
Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United KingdomA Paul Lambert, Kathleen M Gillespie, Glenys Thomson, et al.
Lancet (London, England)|November 9, 2004
The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypesKathleen M Gillespie, Steven C Bain, Anthony H Barnett, et al.
The Lancet. Diabetes & Endocrinology|December 17, 2021
Diabetes and the WHO Model List of Essential MedicinesDavid Beran, Stéphane Besançon, Margaret Ewen, et al.
Diabetes|October 27, 2006
Islet autoimmunity in children with Down's syndromeKathleen M Gillespie, Rachel J Dix, Alistair J K Williams, et al.
Diabetes|October 27, 2004
Activating mutations in the KCNJ11 gene encoding the ATP-sensitive K+ channel subunit Kir6.2 are rare in clinically defined type 1 diabetes diagnosed before 2 yearsEmma L Edghill, Anna L Gloyn, Kathleen M Gillespie, et al.
Diabetes Care|December 19, 2008
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart AssociationJay S Skyler, Richard Bergenstal, Robert O Bonow, et al.
Circulation|December 20, 2008
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart AssociationJay S Skyler, Richard Bergenstal, Robert O Bonow, et al.
Journal of the American College of Cardiology|January 17, 2009
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart AssociationJay S Skyler, Richard Bergenstal, Robert O Bonow, et al.
Pageof 6